New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 19, 2013
10:04 EDTSMS, VRTX, UBS, TOL, AN, NOK, NPTN, EWBC, OSTK, EE, AF, DXPE, BBT, TEF, MMS, ETFCOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Astoria Financial (AF) upgraded to Market Perform from Underperform at Keefe Bruyette... Autonation (AN) upgraded to Hold from Sell at Deutsche Bank... E-Trade (ETFC) upgraded to Market Perform from Underperform at Keefe Bruyette... El Paso Electric (EE) upgraded to Buy from Hold at Jefferies... Maximus (MMS) upgraded to Outperform from Market Perform at Raymond James... Overstock.com (OSTK) upgraded to Buy from Underperform at BofA/Merrill... Toll Brothers (TOL) upgraded to Outperform from Market Perform at Keefe Bruyette... UBS (UBS) upgraded to Buy from Hold at Deutsche Bank... Vertex (VRTX) upgraded to Buy from Hold at Canaccord... Telefonica (TEF) upgraded at Bernstein... BB&T (BBT) upgraded to Buy from Neutral at Hilliard Lyons... East West Bancorp (EWBC) upgraded to Outperform from Market Perform at Keefe Bruyette... DXP Enterprises (DXPE) upgraded to Buy from Neutral at Ascendiant Capital... NeoPhotonics (NPTN) upgraded to Buy from Hold at Needham... Sims Metal (SMS) upgraded to Buy from Neutral at BofA/Merrill... Overstock.com (OSTK) upgraded at BofA/Merrill... Nokia (NOK) upgraded to Market Perform from Underperform at BMO Capital.
News For AF;AN;ETFC;EE;TOL;MMS;OSTK;UBS;TEF;EWBC;VRTX;BBT;NPTN;SMS;DXPE;NOK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
May 21, 2015
10:30 EDTVRTXVertex management to meet with Maxim
Subscribe for More Information
09:15 EDTNOKGerman automakers partnering with PE firm on bid for Nokia unit, Reuters says
Subscribe for More Information
May 20, 2015
16:26 EDTUBSOn The Fly: Top stock stories for Wednesday
Subscribe for More Information
12:33 EDTUBSOn The Fly: Top stock stories at midday
Stocks began the session relatively unchanged from yesterday’s close and continue to trade in a holding pattern as investors await the release of the minutes from the Federal Reserve's last FOMC meeting. ECONOMIC EVENTS: In the U.S., EIA inventory data showed a 2.67M barrel fall in crude stocks, versus expectations for a 1.75M barrel decrease. The Federal Reserve is scheduled to release the minutes from its last rate setting meeting at 2 pm EDT. In Asia, Japan's GDP accelerated to a 2.4% growth pace in the first quarter, which was much better than expected. Japanese stock markets rallied on the news, sending the Nikkei 225 average to its best level in 15 years. COMPANY NEWS: Five of the world's largest banks - Citi (C), JPMorgan Chase (JPM), Barclays (BCS), The Royal Bank of Scotland (RBS) and UBS (UBS) - agreed to pay more than $5B and plead guilty to felony charges related to manipulating foreign currencies and interest rates. In conjunction with previously announced settlements with regulatory agencies in the United States and abroad, today’s resolutions bring the total fines and penalties paid by these five banks for their conduct in the foreign exchange spot market to nearly $9B, the Department of Justice stated... Target (TGT) shares advanced 1% after the retailer's first quarter earnings topped expectations and it raised the low-end of its fiscal year profit forecast. Brian Cornell, chairman and CEO of Target, said the company was pleased with its first quarter traffic and sales, particularly in its signature categories, which drove better-than-expected profitability through improved gross margin and continued expense management. MAJOR MOVERS: Among the notable gainers was Sarepta Therapeutics (SRPT), which rallied 53% after the company announced that, following meetings with the FDA, it would submit its eteplirsen drug to the FDA for approval on a rolling basis, with various components of the application being submitted separately. Eteplirsen is a treatment for Duchenne muscular dystrophy, or DMD. Also higher was Pep Boys (PBY), which gained 14% after The Wall Street Journal said private equity firm Golden Gate Capital and other potential suitors have expressed interest recently in buying the company. Among the noteworthy losers was Etsy (ETSY), which operates an online marketplace to buy and sell handmade items and vintage goods. The stock, which priced its IPO at $16 and opened for trading at $31 per share, dropped 22% to trade near $16.50 after the company issued its first financial report since coming public in April. Also lower were shares of several airline stocks, led by Southwest (LUV), which was down 8% near noon. In a regulatory filing last night, Southwest indicated it expects FY15 capacity growth to increase 7%-8% and to grow another 6%-7% in FY16. Buckingham downgraded Southwest to Neutral from Buy this morning, stating it has a more cautious revenue outlook for the company due to a worsening backdrop as competitors vow to compete aggressively. INDEXES: Near midday, the Dow was down 6.10, or 0.03%, to 18,306.29, the Nasdaq was up 1.65, or 0.03%, to 5,071.69, and the S&P 500 was down 0.49, or 0.02%, to 2,127.34.
10:15 EDTUBSFive banks agree to parent-level guilty pleas in settlement over forex rigging
Subscribe for More Information
10:09 EDTUBSCiti, JPMorgan, RBS, Barclays, UBS agreed to guilty pleas in forex settlement
Subscribe for More Information
10:00 EDTUBSOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:01 EDTUBSUBS ordered to buy back bond funds from investor, Reuters reports
Subscribe for More Information
05:45 EDTUBSUBS upgraded to Buy from Neutral at BofA/Merrill
05:21 EDTUBSUBS enters resolutions with DOJ, Federal Reserve, CT DOB
UBS announced that it has approved entering into resolutions with the US Department of Justice, or DOJ, the Board of Governors of the Federal Reserve System, and the Connecticut Department of Banking, or CT DOB, in their investigations of the global foreign exchange, or FX, markets. This follows the firm's resolutions last November with the Swiss Financial Market Supervisory Authority, UK Financial Conduct Authority and the U.S. Commodity Futures Trading Commission. The bank continues to cooperate with ongoing investigations by other authorities in this industry-wide matter, which include investigations of individuals. As a result of the resolutions, UBS has not been criminally charged for FX conduct. The DOJ will also not file any charges concerning its investigations into the firm's V10 FX-related structured products and its precious metals business. In resolving the FX matter with the DOJ, UBS received conditional immunity from prosecution for EUR/USD collusion from the Antitrust Division, which will also not prosecute UBS for any other FX conduct. This immunity reflects UBS's role as the firm that first reported potential misconduct to the DOJ, and the full cooperation provided to the DOJ and other authorities throughout the world. The DOJ used its sole discretion to terminate its 2012 Non-Prosecution Agreement with UBS related to LIBOR. As a consequence, UBS AG has agreed to plead guilty to one count of wire fraud for conduct in the LIBOR matter, pay a $203M fine and accept a three-year term of probation. This guilty plea for LIBOR by UBS AG relates to the same conduct that was the basis of the plea by the firm's Japanese subsidiary when the firm resolved its LIBOR issues in 2012. The Fed and the CT DOB jointly issued a cease and desist order finding that UBS engaged in unsafe and unsound business practices relating to its FX business. UBS will pay a penalty of $342M to the Fed and has agreed to undertake a series of remedial measures. The firm is fully provisioned for these resolutions. As a consequence, they will have no financial impact on Q2 results.
May 19, 2015
15:42 EDTUBSBanks' settlement over forex rigging to be announced tomorrow, CNBC says
Several banks are said to plan to plead guilty and pay "billions" in fines in a settlement over their roles in foreign exchange manipulation that is expected to be announced Wednesday, according to CNBC's Kate Kelly. Prior media reports have listed Barclays (BCS), Royal Bank of Scotland (RBS), UBS (UBS), JPMorgan (JPM) and Citigroup (C) as having been in talks with U.K. and U.S. authorities for their roles in foreign currency rigging.
14:48 EDTDXPEDXP Enterprises management to meet with William Blair
Group luncheon to be held in New York at 12:30 pm on May 20 hosted by William Blair.
07:56 EDTVRTXGilead for Achillion rumor not ridiculous, but highly unlikely, TheStreet says
Subscribe for More Information
May 18, 2015
13:37 EDTNOKBaidu, Uber teaming up to pursue Nokia's maps unit, Bloomberg reports
Subscribe for More Information
10:01 EDTTOLOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: A10 Networks (ATEN) upgraded to Overweight from Sector Weight at Pacific Crest... Cal-Maine Foods (CALM) upgraded to Overweight from Equal Weight at Stephens... ChemoCentryx (CCXI) upgraded to Overweight from Neutral at JPMorgan... Cheniere Energy Partners LP (CQP) upgraded to Buy from Neutral at Goldman... Chicago Bridge & Iron (CBI) upgraded to Neutral from Sell at Goldman... Continental Resources (CLR) upgraded to Buy from Neutral at Goldman... Ctrip.com (CTRP) upgraded to Overweight from Neutral at JPMorgan... Emerge Energy (EMES) upgraded to Buy from Neutral at Goldman... FEMSA (FMX) upgraded to Overweight from Equal Weight at Morgan Stanley... GoPro (GPRO) upgraded to Perform from Underperform at Oppenheimer... Holly Energy (HEP) upgraded to Buy from Neutral at Goldman... JP Energy (JPEP) upgraded on better visibility on volumes at RBC Capital... Laredo Petroleum (LPI) upgraded to Neutral from Sell at Goldman... Malvern Bancorp (MLVF) upgraded to Outperform from Market Perform at Keefe Bruyette... Newfield Exploration (NFX) upgraded to Buy from Neutral at Goldman... Norsk Hydro (NHYDY) upgraded to Overweight from Neutral at JPMorgan... Owens-Illinois (OI) upgraded to Neutral from Underperform at BofA/Merrill... Penn National (PENN) upgraded to Buy from Neutral at Goldman... Roche (RHHBY) upgraded to Buy from Neutral at UBS... Schnitzer Steel (SCHN) upgraded on stabilizing headwinds at KeyBanc... Seventy Seven Energy (SSE) upgraded to Buy from Hold at Jefferies... Toll Brothers (TOL) upgraded to Neutral from Underperform at Sterne Agee CRT... United Therapeutics (UTHR) upgraded to Buy from Neutral at BTIG... Volvo (VOLVY) upgraded to Neutral from Underweight at JPMorgan... Zayo Group (ZAYO) upgraded to Buy from Neutral at Goldman.
08:31 EDTUBSUBS, NYSE Bonds announce strategic relationship
Subscribe for More Information
08:02 EDTTOLToll Brothers upgraded to Neutral from Underperform at Sterne Agee CRT
Subscribe for More Information
07:12 EDTUBSBarclays expected to face over GBP250M in fines for rigging, Telegraph says
Subscribe for More Information
06:05 EDTTEFAmdocs data management services selected by Telefonica
Subscribe for More Information
May 17, 2015
13:46 EDTVRTXVertex reports Orkambi data, says 'significant improvements' in primary endpoint
Vertex Pharmaceuticals announced that the New England Journal of Medicine published data from the two phase 3 studies of Orkambi, or lumacaftor/ivacaftor, a medicine designed to treat the underlying cause of cystic fibrosis in people ages 12 and older with two copies of the F508del mutation. In November 2014, Vertex submitted an NDA to the FDA for the combination of lumacaftor and ivacaftor. On May 12th, the FDA’s Pulmonary Allergy Drugs Advisory Committee voted 12-1 to recommend approval of Orkambi for people ages 12 and older with two copies of the F508del mutation. The FDA is expected to make a decision by July 5. The New England Journal reports that the studies enrolled 1108 patients who underwent randomization and received Orkambi. In both studies, there were significant improvements in the primary end point in both lumacaftor–ivacaftor dose groups. The difference between active treatment and placebo with respect to the mean absolute improvement in the percentage of predicted FEV ranged 2.6%-4%, which corresponded to a mean relative treatment difference of 4.3 to 6.7%. Pooled analyses showed that the rate of pulmonary exacerbations was 30%-39% lower than in the placebo group. The rate of events leading to hospitalization or the use of intravenous antibiotics was also lower. The incidence of adverse events was generally similar to the placebo group.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use